Protocol-Specified Modification of Immunosuppression Directed to Protocol Biopsy in Kidney Transplantation
NCT ID: NCT02294097
Last Updated: 2014-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2014-11-30
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Non-biopsy
Population in this arm will be adjusted immunosuppressive drug only from the result of tough level.
No interventions assigned to this group
Protocol biopsy
Population in this arm will be adjusted immunosuppressive drug upon both pathological findings and the result of tough level.
Surveillance protocol kidney allograft biopsy
Surveillance protocol biopsy under ultrasound-guided will perform at post-operative day 7, month 3, month 6, month 12, and month 24
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Surveillance protocol kidney allograft biopsy
Surveillance protocol biopsy under ultrasound-guided will perform at post-operative day 7, month 3, month 6, month 12, and month 24
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Recipients who cannot withhold aspirin, clopidogrel, warfarin, etc.
* Non-cooperated recipients
17 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chulalongkorn University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wiwat Chancharoenthana
Chulalongkorn University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wiwat Chancharoenthana, MD.,MSc.
Role: PRINCIPAL_INVESTIGATOR
Chulalongkorn University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University
Bangkok, Bangkok, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WWC-005
Identifier Type: -
Identifier Source: org_study_id